ANI Seeks Growth With Focus On Acquisitions
With new debt financing in place, ANI says it has “additional funds available” for future acquisitions and growth opportunities. The firm also continues to integrate its Canadian operations acquired last August.
You may also be interested in...
ANI Pharmaceutical is set to expand its contract-manufacturing platform after acquiring for US$18 million WellSpring Pharma Services. The firm said the move will also increase its capacity to re-commercialise its pipeline of acquired abbreviated new drug applications (ANDAs) that require a technology transfer from its Baudette facility in Minnesota, US.
Alvogen can sell in the US generic lenalidomide on a volume-limited basis after March 2022, and without volume limitations in early 2026, after settling patent litigation with Celgene relating to the originator’s Revlimid. Dr Reddy's has also settled in Canada.
Alvogen’s Lotus subsidiary and Cambrex are expanding their manufacturing capabilities in Taiwan and Canada respectively. As several firms reveal the results of FDA inspections, the agency slaps United Exchange Corporation with a warning letter.